Business
Johnson & Johnson reports Q4 and Full-Year 2025 results
NEW BRUNSWICK, N.J., January 21, 2026--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Card
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2404,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/0db09bcad6d353b4755f5bec2a2f53c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EI8tk4AKSYXiZxx8mWdRMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/0db09bcad6d353b4755f5bec2a2f53c2","width":960,"height":89},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNGuaYYlUu53b54jTCv18g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yMjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0db09bcad6d353b4755f5bec2a2f53c2","width":1200,"height":112}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisition of Halda Therapeutics","length":288,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"2025 Full-Year reported sales growth of 6.0% to $94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of $11.03 and adjusted EPS of $10.79, both include $(0.10) due to the acquisition of Halda Therapeutics","length":280,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma, the acquisition of Halda Therapeutics, and submission of OTTAVA Robotic Surgical System","length":398,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company issues guidance for 2026 with estimated reported sales of $100.5 Billion or 6.7% at the midpoint, and adjusted EPS4 of $11.53 or 6.9% at the midpoint","length":157,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1123,"olType":false},{"type":"text","content":"NEW BRUNSWICK, N.J., January 21, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today an...